Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side effects ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.

which is currently the highest dose of the drug marketed under the Wegovy brand for obesity. Digging into the data, participants in the 1,407-patient trial started from a mean baseline body weight ...

Novo Nordisk announced that a higher dose of semaglutide (Wegovy) generated higher placebo-adjusted weight loss at 72 weeks among adherent patients than the lower, approved dose (18.3% vs.

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A high-dose form of Novo Nordisk’s obesity drug Wegovy, together with lifestyle intervention, led to greater ...

Weight loss drugs Ozempic and Wegovy have been added to the list of ... the law directs CMS to use data that is aggregated across different dosage, forms and strengths of a drug in the negotiation ...

Novo Nordisk said that patients taking a higher dose of its blockbuster obesity drug Wegovy lost more weight than those on a lower dose without experiencing an increase in side-effects ...